


PHARMACEUTICAL 2020



Checkpoint Therapeutics Inc. Rank 286 of 362





PHARMACEUTICAL 2020



Checkpoint Therapeutics Inc. Rank 286 of 362

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 235% points.

The company's Economic Capital Ratio, given in the ranking table, is -454%, being 151% points below the market average of -303%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 26,966 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 8,119 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 136 |
| Property and Equipment | 0 |
| Research and Development | 19,325 |
| Revenues | 1,708 |
| Selling, General and Administrative Expense | 7,233 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 26,966 |
| Liabilities | 8,119 |
| Expenses | 26,558 |
| Stockholders Equity | 18,847 |
| Net Income | -24,714 |
| Comprehensive Net Income | -24,714 |
| Economic Capital Ratio | -454% |